苏州国匡医药科技

Suzhou Guokuang Pharmaceutical Technology is a clinical-stage Chinese biotechnology company focused on developing innovative small molecule immunotherapies and targeted protein degraders for oncology and immune-mediated diseases. The company's lead candidate, GK201, is a first-in-class oral small molecule CTLA-4 degrader/inhibitor currently in Phase 1/2 clinical trials for advanced solid tumors. Suzhou Guokuang also leverages its proprietary oral PROTAC linker technology platform to develop novel degraders targeting GSPT1, IKZF2, and other oncogenic proteins. Additionally, the company has established strategic partnerships, including a licensing agreement with Adlai Nortye for its preclinical IDO1 inhibitor.